Health activists say new policy may not address the weaknesses in ongoing routine immunisation programmes and would flood poor countries with new vaccines When the global health leaders meet in Geneva from May 21 to 26 for the World Health Organization's 65th General Assembly, introducing new vaccines in the low- and middle-income countries would be high on their agenda. A “global draft vaccine action plan”, available on WHO's website, details the implementation...

A universal pension scheme for social protection must be part of a broader strategy of economic expansion different from the present neoliberal order. INDIA must be one of the worst countries in the world in terms of not providing even minimal social security for most of its people. This is not just a major failure of the development project in the country – it is also a significant cause of...

Doctors across India who encounter patients with tuberculosis will have to disclose the identity, age, sex, and address of each patient to local health authorities under an order issued this week by the Union health ministry. The health ministry said today that it is essential to have complete information as part of its efforts to ensure that patients receive proper diagnosis and therapy and to curb the emergence and spread of...

-The Telegraph The decade-long flow of funds from the Bill and Melinda Gates Foundation into India’s HIV control efforts will stop from June 2013, a foundation official said today, intensifying fears among sections of health activists about the future of the programme. Avahan was the first large-scale health initiative in India to be supported by the foundation, said to be t he world’s largest philanthropic organisation, and will be the first to...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...